MiniMed Launches Compact App-Controlled Insulin Pump in U.S.
Event summary
- MiniMed launched its MiniMed Flex™ system, the company's smallest app-controlled insulin pump, in the U.S. on June 17, 2026.
- The system is paired with the Simplera Sync™ sensor, with compatibility with Abbott's Instinct sensor planned for later this summer.
- The pump is about half the size of other MiniMed pumps and holds 300 units of insulin.
- Real-world results demonstrated 80% Time in Range (TIR) with recommended settings, exceeding worldwide TIR recommendations.
- The MiniMed Flex™ system is FDA cleared for people with type 1 diabetes ages 7 and older, and adults with insulin-requiring type 2 diabetes.
The big picture
MiniMed's launch of the MiniMed Flex™ system represents a significant step in the evolution of diabetes management technology. The compact, app-controlled insulin pump addresses a long-standing need for a device that combines clinical performance with lifestyle flexibility. This launch positions MiniMed to compete more effectively in the growing market for advanced diabetes care solutions, particularly as the industry shifts towards more integrated and user-friendly technologies.
What we're watching
- Market Adoption
- How quickly the MiniMed Flex™ system will be adopted by patients and healthcare providers, given its compact size and app-controlled features.
- Competitive Positioning
- Whether MiniMed can sustain its market position against competitors with similar or advanced technologies.
- Regulatory Approvals
- The pace at which the MiniMed Flex™ system with the Instinct sensor will receive FDA clearance and become commercially available.
Related topics